Ftse Mib
34.165,92
0,01%
DAX
19.909,14
-0,25%
S&P 500
5.917,80
-0,89%
NASDAQ
19.525,77
-1,00%
Bitcoin
91.945,12
-1,68%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ TransCode Therapeutics Inc (RNAZ) TransCode Therapeutics Inc (RNAZ) Notizie

TransCode Therapeutics Inc

RNAZ
3,46
-0,21 (-5,72%)
Ultimo aggiornamento: 17:40:29
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
20/12/202422:10EDGAR2Form 8-K - Current report
19/12/202422:48EDGAR2Form PRE 14A - Other preliminary proxy statements
18/12/202414:00PRNUSTransCode Therapeutics Announces Safety Review Committee..
18/12/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
06/12/202423:05EDGAR2Form S-1 - General form for registration of securities under..
02/12/202422:27EDGAR2Form 8-K - Current report
29/11/202422:25GLOBETransCode Therapeutics Announces Effective Date for 1-for-33..
29/11/202422:21EDGAR2Form 8-K - Current report
27/11/202413:00GLOBETransCode Therapeutics, Inc. Announces $8 Million Private..
25/11/202413:54EDGAR2Form 8-K - Current report
25/11/202413:00GLOBETransCode Therapeutics Announces 1-for-33 Reverse Stock..
13/11/202422:34EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
12/11/202413:00GLOBETransCode Therapeutics Open Letter to Shareholders
06/11/202422:05EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
06/11/202422:01EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
06/11/202422:01EDGAR2Form 8-K - Current report
05/11/202413:00GLOBETransCode Therapeutics Announces Nasdaq Extension to Regain..
28/10/202421:02EDGAR2Form DEF 14A - Other definitive proxy statements
23/10/202413:00GLOBETransCode Therapeutics Announces Safety Review Committee..
15/10/202423:23EDGAR2Form PRE 14A - Other preliminary proxy statements
10/10/202413:00GLOBETransCode Therapeutics Completes Initial Dosing of First..
27/9/202422:02EDGAR2Form 8-K - Current report
17/9/202413:00GLOBETransCode Therapeutics Announces First Patients Treated in..
10/9/202413:00GLOBETransCode Therapeutics Announces Publication of Study with..
05/9/202413:00GLOBETransCode Therapeutics Awarded $2 Million NIH Grant to..
28/8/202412:02EDGAR2Form 8-K - Current report
16/8/202423:04EDGAR2Form 8-K - Current report
15/8/202413:00GLOBETransCode Therapeutics Announces Phase 1 Clinical Trial..
14/8/202422:45EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
26/7/202422:05EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
24/7/202422:05GLOBETransCode Therapeutics, Inc. Announces Closing of Public..
24/7/202415:01EDGAR2Form 8-K - Current report
24/7/202414:18EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
23/7/202404:30GLOBETransCode Therapeutics, Inc. Announces Pricing of Public..
22/7/202422:10EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
22/7/202422:07GLOBETransCode Therapeutics, Inc. Announces Proposed Public..
18/6/202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/6/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202414:00EDGAR2Form 8-K/A - Current report: [Amend]
13/6/202423:06EDGAR2Form 8-K - Current report
10/6/202414:45EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10/6/202413:00GLOBENasdaq Determines That TransCode Therapeutics Has Regained..
07/6/202422:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
07/6/202422:00EDGAR2Form 8-K - Current report
29/5/202415:15GLOBETransCode Therapeutics Reports Positive Data from..
20/5/202422:00EDGAR2Form DEFR14A - Revised definitive proxy soliciting materials
15/5/202423:13EDGAR2Form 8-K - Current report
13/5/202423:08EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
13/5/202414:30GLOBETransCode Therapeutics Open Letter to Shareholders
10/5/202422:50EDGAR2Form PRE 14A - Other preliminary proxy statements
Apertura: 3,65 Min: 3,36 Max: 3,67
Chiusura: 3,67

La tua Cronologia

NASDAQ
RNAZ
TransCode Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network